17,261 trials
Mild Cognitive Impairment · Alzheimer Disease
Primary: Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) — 0.12; 3.27 OD — p=<0.0001
Aplastic Anemia
Primary: Hematologic Response Rate at 6 Months (Week 26) by Investigator — 70.0 Percentage of participants
Overactive Bladder · Urge Incontinence · Fecal Incontinence
Primary: Visual Analog Scale Pain Score — 45; 61 mm
Dental Caries in Children
Primary: Caries Increment — 9.8; 11.3 Number of tooth surfaces — p=0.279
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
Frontotemporal Dementia (FTD)
Primary: Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI) — 7.14; 5.75 score on a scale
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Esophageal Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Assessed by the Investigator — 30.6; 20.6 percentage of participants — p=0.2114
Multiple Myeloma
Primary: Complete Remission Rate — 31; 42 Participants
Infection, Bacterial
Primary: Measurement of Total and Unbound Penicillin-V Concentration — 2.07; 2.8; 5.03; 3.62 mg/L
Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0 Participants
Neurogenic Bladder · Spinal Cord Injuries
Primary: Evaluate Bladder Storage Using Urodynamics — 611; 177.67; 662; 452 mL
Melanoma · Merkel Cell Carcinoma · Other Solid Tumors
Primary: Best Response — 1; 1; 0; 0 Participants
HIV Infections
Primary: Safety Endpoint: Proportion of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive…
Microsatellite Stable (MSS) Colorectal Adenocarcinomas · Colorectal Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 1; 2 Participants